Treatment of advanced HER2-positive breast cancer: 2018 and beyond; Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative; Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors; Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis; Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects; Mammaprint™: a comprehensive review; What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?; VISTA: a promising target for cancer immunotherapy?; Systemic treatment of patients with early breast cancer: recent updates and state of the art; Cancer incidence in Mozambique in 2015–2016: data from the Maputo Central Hospital cancer registry; Cervical cancer screening uptake in women aged between 15 and 64 years in Mozambique; Impact of HIV infection on baseline characteristics and survival of women with breast cancer; Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis; Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors; Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy; Breast cancer subtypes: implications for the treatment and survival of patients in Africa—a prospective cohort study from Mozambique; Satisfação com a especialidade entre os internos da formação específica em Portugal; Quality of life trajectories during the first three years after diagnosis of breast cancer: the NEON-BC study; Survival impact and cost-effectiveness of a multidisciplinary tumor board for breast cancer in Mozambique, sub-Saharan Africa; Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials
